

**Federico Lois**

Twitter: @federicolois

# Techies in Virusland



**What is a performance guy  
doing in Virusland?**





FOR SOME REASON, I FEEL A POWERFUL COMPULSION TO OWN ANY DEVICE WHOSE NAME ENDS IN "-OMETER."

# If the only thing you know how to do is measure...

## Guess what!!!

# Epidemiology

is the study and analysis of the **distribution, patterns** and **determinants of health** and **disease conditions** in defined **populations....**



**You are right!!!**

**MEASUREMENTS, MEASUREMENTS, MEASUREMENTS**



# What are we going to talk about today?

- Epidemic behavior and modeling of infectious diseases.
  - A primer on SARS-Cov-2 epidemic behavior.
  - Some outcomes of our work with Levan Djaparitze.
- Why forecasting is CRAZY hard
  - Why we fail consistently to forecast.
  - What can we do about it.



# Part 1: The disclaimer



# HARDCORE

A large, bold, black letter 'H' is centered in the left half of the white box. The letter is slightly tilted to the right.

**Not Applicable**  
**Sensitive Topic**  
**Forecasting is [H]ARD!!!**


**DOTNEXT CONTENT RATING**



# **Part 2: The fundamentals**




# A primer in evaluation of evidence...



Not all evidence is created equal.

# A primer in evaluation of evidence...



Most of it  
lives **down** here!!!  
That's **BAD**

**Let's talk about models  
Shall we?**



**A model is a group of equations,  
where you can choose what it is data  
and what is unknown.**

- Levan Djaparitze




# Models, models, models...

- Models are abstractions of processes.
- How do we know ...
  - ... we are modeling the right thing?
  - ... we aren't overfitting?
  - ... our theories are correct?
  - ... our calibration is correct?




# Are we overfitting?



- Classic example.
- The problem with complex systems?
  - Overfitting is subtle.
  - Too many free parameters.
  - Solutions are usually non-linear
    - More on this later.
  - You will not know it until it is too late.
    - Induction problem.



# Are we modeling the right thing?

- Huge problem in modeling.
- The problem with complex systems?
  - Is the simplification able to describe the system?
  - Can we measure the difference between predicted and measured values?
  - Are measurements:
    - trustworthy, unbiased, representative,
    - free of systematic observational error?





# Is our calibration correct?



- Huge problem in epidemiology.
- When we measure, what are we measuring, REALLY!!! For ex,
  - $R^*$  (Reproduction number).
  - IFR or CFR
  - Cases or deaths
- This alone can break a model without us even knowing it.



**Federico Andres Lois**

@federicolois



All models are wrong, some are useful. The important part is that we forget that the rest are just plain garbage.

[Traducir Tweet](#)

4:06 p. m. · 5 abr. 2021 · Twitter Web App

# Modeling SARS-Cov-2

- Lots of questions, not many clear-cut answers:
  - ... are asymptomatic contagious?
  - ... what is the mode of transmission?
  - ... what is the spread factor (R knot)?
  - ... what is the lethality by age?
  - ... are there going to be second waves\*
  - ... is seroprevalence a good measurement?
  - ... is the evidence any good?
  - ... does an optimal response exist? \*

\* We asked ourselves these questions in July and responded it by the 13<sup>th</sup> of October.



**When modeling complex systems  
induction just fails...**





**Federico Andres Lois**

@federicolois



What most scientist do not realize is: "Science is about proving yourself wrong, not right."

[Traducir Tweet](#)

2:11 p. m. · 5 abr. 2021 · Twitter Web App

# **Modus Tollens to the rescue**



# Modus Tollendo Tollens

Your most important tool for modeling processes.

$$\frac{P \rightarrow Q, \neg Q}{\therefore \neg P}$$

From Latin: "mode that by denying denies"



# Modus Tollendo Tollens

Your most important tool for modeling processes.

P implies Q

$$P \rightarrow Q, \neg Q$$

---

$$\therefore \neg P$$



# Modus Tollendo Tollens

Your most important tool for modeling processes.

$$P \rightarrow Q, \neg Q$$

---

$$\therefore \neg P$$

P implies Q

but it is the case of not Q

# Modus Tollendo Tollens

Your most important tool for modeling processes.

$$P \rightarrow Q, \neg Q$$

---

$$\therefore \neg P$$

P implies Q

but it is the case of not Q

then we can conclude not P

**What does this mean?**



**YOU ALWAYS HAVE**



**THE HIGH GROUND**

You need just a single counter-example

**How that works?**



# Let's say I have a theory

**Claim:** Obesity is a major factor in deaths of SARS-Cov-2

## Evidence

**Czech Republic:** Obesity rate of **26%** with **2603 deaths per million**

**Switzerland:** Obesity rate of **19.5%** with **1201 deaths per million**

**Argentina:** Obesity rate of **31%** with **1269 deaths per million**

**Norway:** Obesity rate of **23.1%** with **126 deaths per million**

**Egypt:** Obesity rate of **32%** with **120 deaths per million**



Let's say I have a theory

Claim: Obesity is a major factor in deaths of SARS-Cov-2

Evidence

Egypt: Obesity rate of 32% with 120 deaths per million

$$P \rightarrow Q, \neg Q$$

---

$$\therefore \neg P$$

# What can we say about my pet theory?

We can conclude without risking to be wrong

**It's not correct**

# BUT!!!


**There is always a BUT**





# As always, the devil is in the details!!!

My pet theory may be:

- ... just plain wrong!!! *Usually, the most likely case.*
  - ... unable to explain variance (a confounder)
  - ... right, but only at a second or third order contribution.
  - ... incomplete (**P** is missing clauses)
  - ... underspecified (**Q** is ambiguous)
  - ... (**P, Q**) are subjected to systematic observational error
- 

# Systematic Observational Error

Say you have a surveillance system:

- ... you do “randomized population sampling”
- You test **2000** cases in the lab.
- ... you have **10+** years of data with positivity around **10%**


Say some year you have:

- ... an abnormal spike in cases (say 10 times more)
  - Normally: **100.000 cases**
  - This year: **1.000.000 cases (10x)**
- ... you measure lab confirmed positivity
  - and it is compatible with your history.



If from **100,000** cases we send **2,000** to the lab, and **10%** of the cases are influenza, then **10,000** cases are expected to be influenza, and **90,000** are expected to be untypified influenza-like diseases. Clearly no abnormality there, as positivity is compatible with history.

If from **1,000,000** cases we send **2000** to the lab, and **10%** of the cases are influenza, then **100,000** cases are expected to be influenza, and **900,000** are expected to be untypified influenza-like diseases. Is this year compatible with history?



Can we conclude there is **NO** abnormality there?





# Part 3: Modeling SARS-Cov-2

**SARS-CoV-2 waves in Europe: A 2-stratum SEIRS model solution**

By Levan Djaparidze and Federico Lois



# **Some important definitions**

## **(the watch-later glossary)**



# Definitions

**SARS-Cov-2:** RNA Virus from the Betacoronavirus genus.

**COVID-19:** The group of signs and symptoms which define the disease caused by SARS-Cov-2

**PCR+:** Individual with samples positive for RNA sequences of SARS-Cov-2 by Polymerase Chain Reaction

**Ab+:** Positive to antibodies specific to SARS-Cov-2 (IGg/IGm)

**Humoral Immunity:** Immunity conferred by antibody mediated response


**Cellular Immunity:** Immunity conferred by T-cells mediated response.

**Seroprevalence:** Prevalence of Ab+ at a population level

**Infected:** An individual carrying SARS-Cov-2 during the infectious period.

**Case:** A PCR+ individual detected or suspected by epidemiological criteria of carrying SARS-Cov-2 during the period it is thought to be infective.

**Ro (Basic Reproduction Number):** expected number of new infected directly generated by a single infected in the population





# Definitions

**Symptomatic:** A PCR+ individual with unequivocal symptoms for COVID-19

**Presymptomatic:** A PCR+ individual which will be symptomatic in the future on a reasonable time period (5 to 10 days).

**Mild-symptomatic:** A PCR+ individual with non-unequivocal symptoms for COVID-19

**Asymptomatic:** A PCR+ individual without symptoms for COVID-19.

**Suspected Death:** An individual death which meets the definition of symptoms for COVID-19

**Confirmed Death:** A PCR+ individual death (no distinction)

**Clinically Confirmed Death:** A symptomatic individual death

**NPIs:** Non-Pharmaceutical Interventions like social distancing, closed schools, masks, etc.

# Definitions

**Cohort:** A population segment with a specific characteristic.

**Compartmental models:** Simplified mathematical models of epidemic behavior where the order of the letters shows the flow pattern between compartments.

**Homogeneous models:** Models in which individuals share the same parameters along the population in the cohort.

**Heterogeneous models:** Models in which individuals may have different parameters along the population in a cohort.

**SIR Model:** Susceptible-Infected-Recovered model [Kermack & McKendrick, 1927].

**SEIRS Model:** Susceptible-Exposed-Infected-Recovered-Susceptible model (SEIR with temporary immunity becoming susceptible again).

**ABMs:** Agent-based models where simulation can be anything, from an individual to an organization, or even a country where each cell is an individual agent interacting at different levels of details with other agents.

# 2-stratum SEIRS model

- 2 parallel feed-forward compartmental SEIRS models.
- Age stratified with 2 cohorts
  - Healthy under 60, Vulnerable ( >60 or not healthy )
- Models explicitly NPIs through averaging (isolation).
  - For the math inclined, similar idea to mean-field theory.
- **Both locations and viral parameters are fixed.**
- Objectives:
  - Estimate total immunity on naïve populations.
    - Do they have enough susceptible to fuel another wave?
  - Disambiguate epidemic behavior
    - Is dynamic at Stockholm equal to Madrid's?

# Basic SEIR model

$$\frac{dS}{dt} = -\frac{\beta IS}{N}$$

$$\frac{dE}{dt} = \frac{\beta IS}{N} - \sigma E$$

$$\frac{dI}{dt} = \sigma E - \gamma I$$

$$\frac{dR}{dt} = \gamma I$$

$$S + E + I + R = N,$$


when  $N$  is constant for us

$\beta$  = transmission rate

$\sigma$  = latency


$\gamma$  = recovery rate

# Basic SEIR model



$$\frac{dS}{dt} = -\frac{\beta IS}{N}$$


# Basic SEIR model



$$\frac{dS}{dt} = -\frac{\beta IS}{N}$$

$$\frac{dE}{dt} = \frac{\beta IS}{N} - \sigma E$$


# Basic SEIR model



$$\frac{dE}{dt} = \frac{\beta IS}{N} - \sigma E$$

$$\frac{dI}{dt} = \sigma E - \gamma I$$

# Basic SEIR model





$$\frac{dI}{dt} = \sigma E - \gamma I$$

$$\frac{dR}{dt} = \gamma I$$



# 2 stratum - SEIR model





**A model is a group of equations,  
where you can choose what it is data  
and what is unknown.**

- Levan Djaparitze



## 2 stratum – THE DATA

- Viral parameters are data (not unknowns).
  - $R_0 = 3.3$ ,  $D_0 = 2$  days,  $E_0 = 5$  days,
  - $IFR_{vul} = 0.92\%$ ,  $IFR_{non\_vul} = 0.0035\%$ ,
  - $P_{non\_vul\_una} = 7\%$ , etc.
- Location parameters are data (not unknowns).
  - Population, Population at risk, etc
- Reported daily deaths
- Seroprevalence ratio
  - This one is huge... more on this later

## **THE UNKNOWN:**

**Total number of infected individuals  
from a fully naïve population**



**Can we forecast now?**



# The free parameters

- The model was designed to be fitted
  - Why fitting?
  - What data should we fit?
  - Avoid free parameters like the plague.
  - Aren't virus and location parameters, free parameters?
- 2-stratum free parameters
  - Average NPI level (isolation) for the vulnerable
  - Average NPI level (isolation) for the healthy




# DEMO: Fitting Madrid






# The dangers of under-determination




Healthy <60	Vulnerable	Fitted Deaths
0.95	0.183	8391
0.9	0.297	8391
0.85	0.404	8391
0.8	0.501	8391
0.78	0.537	8391
0.76	0.569	8391
0.748	0.588	8391
0.72	0.628	8391
0.7	0.655	8391
0.65	0.716	8391
0.6	0.766	8391
0.55	0.808	8391
0.5	0.841	8391
0.4	0.89	8391
0.3	0.92	8391
0.2	0.939	8391
0.1	0.951	8391

Let's look at what happen when we visually inspect them.






Healthy <60: 0.5  
 Vulnerable: 0.841



Healthy <60: 0.748  
 Vulnerable: 0.588




Healthy <60: 0.3  
 Vulnerable: 0.92




**Are we there yet?**



# The dangers of under-determination




Healthy <60: 0.3  
Vulnerable: 0.92



Healthy <60: 0.748  
Vulnerable: 0.588


# The dangers of under-determination

**Final deaths: 13085**




Healthy <60: 0.3  
Vulnerable: 0.92

**Final deaths: 16583**




Healthy <60: 0.748  
Vulnerable: 0.588

# The dangers of under-determination



Healthy <60	Vulnerable	Final Deaths
0.95	0.183	17440
0.9	0.297	17260
0.85	0.404	17065
0.8	0.501	16843
0.78	0.537	16746
0.76	0.569	16647
0.748	0.588	16583
0.72	0.628	16430
0.7	0.655	16310
0.65	0.716	15971
0.6	0.766	15569
0.55	0.808	15086
0.5	0.841	14520
0.4	0.89	13085
0.3	0.92	11304
0.2	0.939	8987
0.1	0.951	8400

# The dangers of under-determination



Healthy <60	Vulnerable	Seroprevalence Ratio	Final Deaths
0.95	0.183	0.51	17440
0.9	0.297	0.58	17260
0.85	0.404	0.65	17065
0.8	0.501	0.72	16843
0.78	0.537	0.75	16746
0.76	0.569	0.77	16647
0.748	0.588	0.79	16583
0.72	0.628	0.83	16430
0.7	0.655	0.86	16310
0.65	0.716	0.93	15971
0.6	0.766	1	15569
0.55	0.808	1.07	15086
0.5	0.841	1.15	14520
0.4	0.89	1.29	13085
0.3	0.92	1.42	11304
0.2	0.939	1.53	8987
0.1	0.951	1.61	8400

**If you don't fight back.  
It gets worse and worse.**







**Are we there yet?**



# Why overdetermination is important?




**Stockholm**



**Madrid**




# Why overdetermination is important?



**Stockholm**

Seroprevalence Ratio: 1.7




**Madrid**

Seroprevalence Ratio: 0.79




# Why overdetermination is important?



**Stockholm**

Seroprevalence Ratio: 1.7



**Madrid**

Seroprevalence Ratio: 0.79

**Are we there yet?**



# Part 4: Forecasting

**SARS-CoV-2 waves in Europe: A 2-stratum SEIRS model solution**

By Levan Djaparidze and Federico Lois



## **THE UNKNOWN:**

**Total number of infected individuals  
from a fully naïve population**



# THE UNKNOWN: Immunity Estimation





# Immunity Estimation

- Getting the right data is key.
  - **Cases** is a bad choice; date of reporting is just awful.
  - **Confirmed Deaths** by **date of death** is the most reliable.
- High quality seroprevalence study:
  - Randomized sampling (representative),
  - Age stratified to recover the seroprevalence ratio
- Find viral parameters that can explain all locations. (HARD)
  - Evaluating scientific literature is important.
  - **Tollendo Tollens ALL THE WAY**
  - For ex.  $R_0=3.3$  can explain *all first waves*.



# Immunity Estimation (Our results)

- Immunity estimation [Deaths per million] *if normal life:*
  - Madrid: 41% [2461 / Million]
  - Catalonia: 23% [2766 / Million]
  - Paris\*: 23% [2297 / Million]
  - London\*: 33% [1930 / Million]
  - Brussels: 49% [1814 / Million]
  - Stockholm: 62% [1575 / Million]

***No location can return to normal life  
without having a second wave***



# Why use the seroprevalence ratio?




Source: <https://twitter.com/dobssi>

***And Herd Immunity Threshold (HIT)  
is 10% higher now!!!!***

# Immunity Estimation (Our results)

Location	At July 4 <sup>th</sup> , 2020	Predicted	Actual
Madrid	1259	2461	2211
Catalonia	734	2766	1776
Brussels	854	1814	2056
Stockholm	968	1575	1715
London	760	1930	1725
Paris	620	2297	1731

**What if the virus changes?**  
**The UK Variant (30% more transmissible)**  
 **$R_0=4.3$**



# Immunity Estimation (UK Variant)

Location	At July 4 <sup>th</sup> , 2020	Predicted	Actual
Madrid	1259	2507 (+46)	2211
Catalonia	734	2896 (+130)	1776
Brussels	854	2042 (+228)	2056
Stockholm	968	2050 (+475)	1715
London	760	2046 (+116)	1725
Paris	620	2406 (+109)	1731


# What if a virus doesn't kill anyone?

## The harmless virus

### IFR=0

[We know that is not true here, but play along]







# Surprise!!!

- Madrid population
- No mitigation
- 404 deaths per million
- Seroprevalence Ratio: 0.88





- Madrid population
- Pandemic mitigation + Normal Life
- 368 deaths per million
- Seroprevalence Ratio: 0.79

**More Surprises!!!**



**What is the probability of dying while positive from a virus that does not kill you?**

**$P(\text{dying} \mid \text{positive}) P(\text{positive})$**



# Background mortality as a confounder

- There are 2 ways one can be positive at time of death.
  - A PCR+ diagnostic up to x days before death.
  - Viral shedding will cause PCR- to be delayed.
- We averaged both as window of positivity
  - We use 17 days; some countries use 28 days for the stats.

## Sanity checks


**If your model doesn't show deaths, you are doing it wrong.**



# 15% of SARS-Cov-2 positive deaths are 'with' the virus

$$P(\text{dying} \mid \text{other\_cause}) * P(\text{dying} \mid \text{positive})$$

Östergötland, Sweden (245 deaths)

- 60% contributing factor (148 deaths)
  - 25% dominant cause (61 deaths)
  - 15% unrelated ('with') (36 deaths)
- 

**If natural mortality can impact the observations.  
Can it impact the immunity estimation?**



**How sensitive is the model to measurement error?**



# Sensitivity Estimation

Variable name	Variable values	Immunity value	Sensitivity (multiplier)
	Point (Min : Max)	Point (Min : Max)	
Ro	3.3 (2.5 : 4.0)	41% (41% : 41%)	≈ 0
Do	2 (1.33 : 5)	41% (41% : 41%)	≈ 0
Eo	5 (4 : 6)	41% (41% : 41%)	≈ 0
RtoD	11 (9 : 13)	41% (41% : 41%)	≈ 0
So	1.00 (0.9 : NA)	41% (51% : NA)	-2.44
IFR_vul	0.0092 (0.0077 : 0.0104)	41% (48% : 37%)	-0.85
IFR_non_vul	0.000035 (0.000029 : 0.000041)	41% (41% : 41%)	≈ 0
P_vul_u60	0.0342 (0.0274 : 0.0401)	41% (42% : 41%)	-0.06
P_non_vul_una	0.07 (0.05 : 0.09)	41% (41% : 41%)	≈ 0
T1	180 (150 : 210)	41% (41% : 41%)	≈ 0
PRLI	0.00 (NA : 0.50)	41% (41% : 41%)	≈ 0
Ma	7 (1 : 14)	41% (41% : 41%)	≈ 0
A_o60	0.21 (0.17 : 0.25)	41% (42% : 41%)	-0.06
A_u60	0.52 (0.42 : 0.62)	41% (40% : 43%)	+0.21
TAK	0.35 (0.29 : 0.42)	41% (41% : 42%)	+0.07
APTP	17 (13 : 21)	41% (43% : 40%)	-0.17
ICU_pd	0.45	NA	NA
ICU_h_dur	10 days	NA	NA
vEff	0.77	NA	NA

Table A.1. Madrid immunity level estimation (Recovered/pop on July 2020) sensitivity for virus parameters.

***Fitted Immunity Estimation behaves differently than most expect.***

# Sensitivity Estimation

Variable name	Variable values	Immunity value	Sensitivity (multiplier)
	Point (Min : Max)	Point (Min : Max)	
Pop	6.662M (5.33M : 8M)	41% (51% : 34%)	-1.23
P_o60	0.233 (0.186 : 0.279)	41% (49% : 35%)	-1.00
con_oD	.. (*0.8 : *1.2)	41% (33% : 49%)	+0.98
sero_day	217 (-21 days : +21 days)	41% (41% : 41%)	≈ 0
sero_u60_o60	0.79 (0.66 : 0.95)	41% (36% : 47%)	+0.75
Iso_1_real	99 (-5 days : +5 days)	41% (41% : 41%)	≈ 0
Iso_1_dur	102 (-21 days : +21 days)	41% (41% : 41%)	≈ 0
PYDR_vul	0.031 (0.025 : 0.038)	41% (42% : 40%)	-0.14
PYDR_non_vul	0.0014 (0.001 : 0.0018)	41% (41% : 41%)	≈ 0


Table A.2. Madrid immunity level estimation (Recovered/pop) sensitivity for location parameters.

***Fitted Immunity Estimation behaves differently than most expect.***






# Playing "What-if"



Madrid population  
Second wave with normal life  
Seroprevalence Ratio: 0.79  
2487 / Million

# Playing "What-if"



Madrid population  
Sweden like mitigation  
Seroprevalence Ratio: 1.55  
1769 / Million

**If we can estimate ‘What-if’ based on evidence.  
Can we find optimal strategies?**




# Death Minimizing

- Back in March we can find the optimal strategy.
- The objective is always to return to normal life.
- Sweden on the first wave was close, but not optimal.

Metropolitan area	Stockholm	Madrid	Catalonia	Brussels	Paris*	London*
Back in March 2020 N-day death minimizing + NL	1115 (10 ICU) 97-day (0.941, +0.17)	1269 (23 ICU) 102-day (0.941, +0.16)	1257 (15 ICU) 100-day (0.941, +0.07)	1011 (10 ICU) 101-day (0.941, +0.23)	1019 (9 ICU) 113-day (0.941, +0.18)	923 (9 ICU) 104-day (0.941, +0.26)
Fitted + 90-day death minimizing with 0.00 to healthy <60 +NL	1579 (2 ICU) (0.25, 0.00)	2426 (14 ICU) (0.37, 0.00)	2325 (25 ICU) (0.71, 0.00)	1765 (8 ICU) (0.35, 0.00)	1911 (19 ICU) (0.78, 0.00)	1798 (16 ICU) (0.60, 0.00)
Fitted + 90-day death minimizing + NL	1454 (2 ICU) (0.941, -1.98)	1834 (15 ICU) (0.941, -0.84)	1630 (34 ICU) (0.941, -0.43)	1297 (9 ICU) (0.941, -0.96)	1384 (28 ICU) (0.941, -0.35)	1314 (17 ICU) (0.941, -0.50)

Table 8 – Final deaths per million (ICU/100K), isolation to vulnerable (with 0.94 maximum), and isolation to healthy <60 for various strategies (beginning on lockdown day) and followed by normal life.

# Death Minimizing



**Can we find optimal strategies EVEN with vaccines?**




# The Vaccine Gamble





- From game theory:
  - A gamble on the expectation of final deaths.
- It is solved though an oracle mechanism.
  - The Oracle 'knows' when a vaccine will be available.
  - The System calculates the expectation of final deaths.
- Assumptions:
  - The vaccine is ve+ 100% [No deaths after vaccine]
  - It can be inoculated to the whole population in 1 day.

**There is NO better scenario for a vaccine!!!**



# After the first wave, what do we do?



-  120-day fitted + 180-day (death minimizing for no vaccine) (0.65, -0.02) + NL. Total final deaths 13522 (2029) (6 ICU/100K).
-  120-day fitted + 180-day (death minimizing for no vaccine) (0.94, -0.24) + NL. Total final deaths 11034 (1656) (4 ICU/100K).
-  120-day fitted + 180-day (0.65,0.4) + Normal Life. Total final deaths 16573 (2487) (19 ICU/100K)
-  120-day (death minimizing for no vaccine) (0.94, 0.17) + Normal Life. Total final deaths 8420 (1264) (15 ICU/100K)



**What if we are wrong?**  
**What if it is more lethal than we estimated?**




**A final thought...**

**Can an ebola patient avoid mandatory isolation?**



# The problem

- Not a new problem, Mary Mallon [1869-1938]
  - Chronic typhoid fever patient.
  - Required a ruling from the Supreme Court.
  - Not the only case.
- Solution requires to solve many extremes.
  - Bubble-Boy: Doesn't damage anyone, everyone damages him.
  - Chronic-Ebola: Damages everyone, nobody damages him.
  - Novel-Virus: Unknown damage function.




**Our proposal:  
Isolation Exemption Insurance**



**One more thing...**

If from **100,000** cases we send **2,000** to the lab, and **10%** of the cases are influenza, then **10,000** cases are expected to be influenza, and **90,000** are expected to be untypified influenza-like diseases. Clearly no abnormality there, as positivity is compatible with history.

If from **1,000,000** cases we send **2000** to the lab, and **10%** of the cases are influenza, then **100,000** cases are expected to be influenza, and **900,000** are expected to be untypified influenza-like diseases. Is this year compatible with history?



**What can you say about the distribution of viruses present on the part of the sample that is untypified?**

**Did they all grow at the same rate as influenza?**

**Do both years have the same hidden distribution?**

**Do all viruses find immunity weaknesses all at once?**

**Did you really think this was hypothetical? 😊**





**Flunami:** an extremely large increase in the number of people suffering from flu (=a common infectious disease making you feel hot, weak and tired)

Macmillan dictionary

South Korea **Flu sweeps through Waiouru military base**


New Zealand

Data suggests this is a serious year for the flu, with a higher number of cases, hospitalisations and deaths recorded than at the same time point in previous years. But there's more to the story.

"Out of 1,129 people across the country with flu-like symptoms, 63 died. Until now, there were 63 deaths in total, with 30 in each in Mon State and Sagaing Region, and 33 in the other regions.

From January to October 4 this year, out of 540 influenza-like illness (ILI) patients, 127 were H1N1 patients; 23, influenza A (H3N2) patients; and 50, influenza B patients. Out of 1,301 severe acute respiratory infection (SARI) patients, 448 were A (H1N1) patients; 39, influenza A (H3N2) patients; and 78, influenza B patients.

Several countries including Myanmar are experiencing a flu wave. In Myanmar, there were 91,873 H1N1 cases in China, 7,846 cases in Myanmar, 407 cases in Thailand, 654 cases in Malaysia and 206 cases in Singapore. Myanmar is the most affected country.




Note: According to Google, "numbers represent search interest relative to the highest point on the chart for the given region and time. A value of 100 is the peak popularity for the term. A value of 50 means that the term is half as popular. A score of 0 means there was not enough data for this term".

Source: [Google Trends](#) · [Get the data](#)

percentage of cases during flu season in

to June



australia

nippon.com

**NEVER ASSUME THE DISTRIBUTION  
OF THE VARIABLES YOU DON'T MEASURE**



# Want to know more?

Start here!!!

- SARS-CoV-2 waves in Europe : A 2-stratum SEIRS model solution:  
<https://www.medrxiv.org/content/10.1101/2020.10.09.20210146v3>
- SARS-CoV-2 waves in Europe simulator: [www.sars2seir.com/paper-12-2020/](http://www.sars2seir.com/paper-12-2020/)
- Detection of Respiratory Viruses in Deceased Persons, Spain, 2017  
[https://wwwnc.cdc.gov/eid/article/24/7/18-0162\\_article](https://wwwnc.cdc.gov/eid/article/24/7/18-0162_article)
- Modeling strict age-targeted mitigation strategies for COVID-19  
<https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0236237>
- Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19  
<https://pubmed.ncbi.nlm.nih.gov/32979941/>
- Virological assessment of hospitalized patients with COVID-2019  
<https://www.nature.com/articles/s41586-020-2196-x>
- Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study  
[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)31483-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31483-5/fulltext)

**Thank you for coming!**  
**I will be at the discussion zone**  
**to answer questions.**

